Breakthrough Insights New Clinical Trial Results Unveil Potential Of Incretin Therapies

---

Advances in Incretin Therapies Highlighted at ADA Meetings This transcript has been modified for clarity.
During this year’s American Diabetes Association (ADA) meetings, incretin therapies took center stage, with an extensive array of studies examining both novel and existing medications. The buzz surrounding these therapies is palpable, and I aim to simplify the discussion surrounding them, despite the often challenging pronunciations of the pharmaceutical names involved.
Three primary focus areas emerged regarding incretin therapies. First, there was an emphasis on innovative combinations of various medications. Second, the introduction of new delivery methods, particularly an oral formulation, promises greater convenience for patients. Third, extended activity durations of these agents aim to enhance patient adherence.
Innovative Drug Combinations The first noteworthy combination discussed is CagriSema, which merges semaglutide and cagrilintide, a long-acting amylin analog. While amylin has been recognized in previous treatments, this latest formulation combines a dose of 2.4 mg of semaglutide with cagrilintide.
Key findings were presented from the REDEFINE trials, examining the effects of these new agents on weight loss in various cohorts—both overweight or obese individuals without type 2 diabetes and those with the condition.
In REDEFINE 1, involving 3,417 participants who were overweight or obese but not diabetic, CagriSema produced a remarkable 20% weight loss, outpacing the 15% loss seen with semaglutide alone and the 12% resulting from cagrilintide alone.
REDEFINE 2 focused on 1,206 individuals with obesity and type 2 diabetes, revealing a noteworthy 13.7% weight loss with CagriSema, compared to just 3.4% in the placebo group. This weight loss pattern is consistent across similar therapies, with non-diabetic participants typically experiencing greater results.
The DREAMS-1 trial spotlighted a weekly GLP-1 receptor agonist in conjunction with a glucagon receptor agonist named mazdutide, specifically in a Chinese population with type 2 diabetes. The trial showed impressive A1c reductions and significant weight loss over 24 weeks, demonstrating the agent’s potential in improving management for these patients.
Novel Delivery Methods The ACHIEVE-1 trial examined an oral formulation of a GLP-1 receptor agonist, known as orforglipron, in individuals with type 2 diabetes. Unlike injectable therapies, this small-molecule agent offers an easier administration through conventional pill ingestion. The results indicated A1c reduction and approximately 8% weight loss, though gastrointestinal (GI) side effects did persist.
This oral option may serve as an introductory step for patients adapting to GLP-1 therapies, even if it falls short of the stronger benefits associated with injectable compounds.
Long-Lasting Effects with Minimal Muscle Loss Another intriguing investigation is the BELIEVE trial, where semaglutide was combined with a monoclonal antibody, bimagrumab, aimed at enhancing muscle mass retention while reducing fat. Evaluated among overweight or obese individuals without type 2 diabetes, various dosages were tested across 507 participants. Notably, while standalone semaglutide resulted in a 7.9% loss of lean mass, the addition of bimagrumab saw a slight gain in lean mass, presenting a promising avenue in reducing adverse effects related to body composition during weight loss procedures.
Side Effects and Considerations Although promising, many of the aforementioned agents do pose significant GI side effects. For example, the newly assessed MariTide—a GLP-1 receptor agonist and GIP antagonist combination administered monthly—recorded extraordinarily high rates of nausea and vomiting. In studies, the rates soared to between 77% and 87% for nausea in treated individuals, a major factor for participant discontinuation.
Such GI effects are common across incretin therapies, warranting cautious prescribing practices, including microdosing to enhance patient tolerance. It’s crucial to strike a balance in weight loss rates to encourage sustainable health improvements while minimizing adverse experiences associated with rapid weight loss.
If managed correctly, incretin-based therapies could revolutionize diabetes and obesity treatments. As these studies unfold, health care professionals must remain attuned to both the benefits and potential drawbacks of these evolving therapies.
This summary brings key updates from the ADA meetings to a broader audience interested in the future of diabetes management and obesity treatment methodologies.


Source link

---